A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (CYPRESS - 1)

June 22, 2018
https://clinicaltrials.gov/ct2/show/NCT03382899
Cancer - Lung
Principal Investigator: Igor I Rybkin, MD
lung cancer, lung, cancer, CYPRESS, ARMO
Accepting Participants